Article information
La hepatitis crónica por el virus de la hepatitis C (VHC) es una de las principales causas de morbilidad y mortalidad en los individuos infectados por el virus de la inmunodeficiencia humana (VIH) en los países desarrollados. Los pacientes coinfectados presentan una más rápida evolución a cirrosis y mayor riesgo de toxicidad hepática del tratamiento antirretroviral. El tratamiento de la hepatitis crónica C en pacientes VIH+ es menos eficaz que en pacientes monoinfectados por el VHC y requiere una especial experiencia.
Palabras clave:
Coinfección
Virus de la inmunodeficiencia humana
Virus de la hepatitis C
Chronic hepatitis due to hepatitis C virus (HCV) infection is now one of the leading causes of morbidity and mortality among HIV-infected individuals. Coinfected patients present an accelerated course toward cirrhosis and an enhanced risk of liver toxicity associated with the use of antiretroviral agents. Treatment of chronic hepatitis C in HIV+ patients is less efficacious than in HCV-monoinfected individuals and requires particular expertise.
Keywords:
Co-infection
Human immunodeficiency virus
Hepatitis C virus
Full text is only aviable in PDF
Bibliografía
[1.]
L. Martín-Carbonero, V. Soriano, E. Valencia, J. García-Samaniego, M. López, J. González-Lahoz.
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.
AIDS Res Hum Retroviruses, 17 (2001), pp. 1467-1472
[2.]
I. Bica, B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, et al.
Increasing mortality due to end-stage liver disease in patients with HIV infection.
Clin Infect Dis, 32 (2001), pp. 492-497
[3.]
E. Rosenthal, C. Perronne, P. Veyssier, G. Raguin, GERMVIC Study Group.
Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.
Clin Infect Dis, 32 (2001), pp. 1207-1214
[4.]
E. Rosenthal, M. Poiree, C. Pradier, C. Perronne, D. Salmon-Ceron, L. Geffray, et al.
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).
AIDS, 17 (2003), pp. 1803-1809
[5.]
K. Gebo, M. Diener-West, R. Moore.
Hospitalization rates differ by hepatitis C status in an urban HIV cohort.
J Acquir Immune Defic Syndr, 34 (2003), pp. 165-173
[6.]
R. Detels, A. Muñoz, G. McFarlane, L.A. Kingsley, J.B. Margolick, J. Giorgi, et al.
Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.
JAMA, 280 (1998), pp. 1497-1503
[7.]
J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators.
N Engl J Med, 338 (1998), pp. 853-860
[8.]
E.L. Murphy, A.C. Collier, L.A. Kalish, S.F. Assmann, M.F. Para, T.P. Flanigan, Viral Activation Transfusion Study Investigators. et al, et al.
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
Ann Intern Med, 135 (2001), pp. 17-26
[9.]
V. Soriano, M. Puoti, M. Sulkowski, S. Mauss, P. Cacoub, A. Cargnel, et al.
Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel.
AIDS, 18 (2004), pp. 1-12
[10.]
A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, G. Palu, et al.
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
J Hepatol, 42 (2005), pp. 615-624
[11.]
M. Sulkowski, D. Thomas.
Hepatitis C in the HIV-infected person.
Ann Intern Med, 138 (2003), pp. 197-207
[12.]
N. Bräu.
Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy.
AIDS, 17 (2003), pp. 2279-2290
[13.]
J. Rockstroh, A. Mocroft, V. Soriano, C. Tural, M. Losso, A. Horban, et al.
Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy.
J Infect Dis, 192 (2005), pp. 992-1002
[14.]
J. Rockstroh, U. Spengler.
HIV/HCV coinfection.
Lancet Infect Dis, 4 (2004), pp. 437-444
[15.]
H. Hagan, H. Thiede, N. Weiss, S. Hopkins, J. Duchin, E. Alexander.
Sharing of drug preparation equipment as a risk factor for hepatitis C.
Am J Public Health, 91 (2001), pp. 42-46
[16.]
A. Rauch, M. Rickenbach, R. Weber, B. Hirschel, P.E. Tarr, H.C. Bucher, et al.
Association of unsafe sex and increased incidence of hepatitis C infection in HIV-infected men who have sex with men.
Clin Infect Dis, 41 (2005), pp. 395-402
[17.]
J. Ghosn, S. Pierre-Francois, V. Thibault, C. Duvivier, R. Tubiana, A. Simon, et al.
Acute hepatitis C in HIV-infected men who have sex with men.
HIV Med, 5 (2004), pp. 303-306
[18.]
B. Cribier, D. Rey, C. Schmitt, J.M. Lang, A. Kirn, F. Stoll-Keller, et al.
High hepatitis C viremia and impaired antibody response in patients coinfected with HIV.
AIDS, 9 (1995), pp. 1131-1136
[19.]
M. Beld, M. Penning, M. Van Putten, A. Van den Hoek, M. Damen, M.R. Klein, et al.
Low levels of HCV RNA in serum, plasma, and PBMCs of IDUs during long antibody-undetectable periods before seroconversion.
Blood, 94 (1999), pp. 1183-1191
[20.]
S. George, J. Gebhardt, D. Klinzman, M.B. Foster, K.D. Patrick, W.N. Schmidt, et al.
Hepatitis C viremia in HIV-infected individuals with negative HCV antibody tests.
J Acquir Immun Defic Syndr, 31 (2002), pp. 154-162
[21.]
C. Sabin, P. Telfer, A. Phillips, S. Bhagani, C. Lee.
The association between HCV genotype and HIV disease progression in a cohort of hemophiliacs.
J Infect Dis, 175 (1997), pp. 164-168
[22.]
L. Piroth, M. Duong, C. Quantin.
Does HCV co-infection accelerate clinical and immunological evolution of HIV infected patients?.
AIDS, 12 (1998), pp. 381-388
[23.]
L. Piroth, M. Grappin, L. Cuzin.
HCV coinfection is a negative prognostic factor for clinical evolution in HIV-positive patients.
J Viral Hepatitis, 7 (2000), pp. 302-308
[24.]
G. Haydon, P. Flegg, C. Blair, R. Brettle, S. Burns, P. Hayes.
The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 485-489
[25.]
C. Staples, D. Rimland, D. Dudas.
Hepatitis C in the HAVACS: the effect of coinfection on survival.
Clin Infect Dis, 29 (1999), pp. 150-154
[26.]
G. Greub, B. Ledergerber, M. Battegay, P. Grob, L. Perrin, H. Furrer, et al.
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfections.
Lancet, 356 (2000), pp. 1800-1805
[27.]
V. Soriano, J.C. Martín, J. González-Lahoz.
HIV-1 progression in hepatitis C-infected drug users.
Lancet, 357 (2001), pp. 1361-1362
[28.]
J. Macías, I. Melguizo, F. Fernández-Rivera, A. García-García, J. Mira, A. Ramos, et al.
Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 775-781
[29.]
M. Sulkowski, R. Moore, S. Mehta, R. Chaisson, D. Thomas.
Hepatitis C and progression of HIV disease.
JAMA, 288 (2002), pp. 199-206
[30.]
E. Tedaldi, R. Baker, A. Moorman, C. Alzola, J. Furhrer, R. McCabe, et al.
Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART.
Clin Infect Dis, 36 (2003), pp. 363-367
[31.]
F. Dronda, J. Zamora, S. Moreno, A. Moreno, J.L. Casado, A. Muriel, et al.
CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use.
AIDS, 18 (2004), pp. 2210-2212
[32.]
M. Klein, R. Lalonde, S. Suissa.
The impact of hepatitis C virus co-infection on HIV progression before and after highly active antiretroviral therapy.
J Acquir Immune Defic Syndr, 33 (2003), pp. 365-372
[33.]
E. Daar, H. Lynn, S. Donfield.
HCV load is associated with HIV-1 disease progression in hemophiliacs.
J Infect Dis, 183 (2001), pp. 589-595
[34.]
T.W. Yoo, S. Donfield, A. Lail, H.S. Lynn, E.S. Daar.
Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease.
J Infect Dis, 191 (2005), pp. 4-10
[35.]
T. Laskus, M. Radkowski, A. Piasek, M. Nowicki, A. Horban, J. Cianciara, et al.
HCV in lymphoid cells of patients coinfected with HIV-1: evidence of active replication in monocytes/macrophages and lymphocytes.
J Infect Dis, 181 (2000), pp. 442-448
[36.]
Núñez M, Benito J, López M, González-Lahoz J, Soriano V. Hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. En: Program and abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2003; Chicago, Illinois. Abstract H-1717.
[37.]
R. Chung, S. Evans, Y. Yang, D. Theodore, H. Valdez, R. Clark, et al.
Immune recovery is associated with persistent rise in HCV-RNA, infrequent liver test flares, and is not impaired by HCV in coinfected subjects.
AIDS, 16 (2002), pp. 1915-1923
[38.]
R. Reisler, C. Han, W. Burman, E. Tedaldi, J. Neaton.
Grade 4 events are as important as AIDS events in the era of HAART.
J Acquir Immune Defic Syndr, 34 (2003), pp. 379-386
[39.]
E. Melvin, E. Elsey, J. Arnold, R. Murphy.
The impact of coinfection with hepatitis C virus and HIV on tolerability of antiretroviral therapy.
AIDS, 14 (2000), pp. 463-465
[40.]
A. Mocroft, A. Phillips, V. Soriano, J. Rockstroh, A. Blaxhult, C. Katlama, et al.
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/ physician choice in patients with hepatitis C coinfection.
AIDS Res Hum Retroviruses, 21 (2005), pp. 527-536
[41.]
R. Rodríguez-Rosado, J. García-Samaniego, V. Soriano.
Hepatotoxicity after introduction of highly active antiretroviral therapy.
AIDS, 12 (1998), pp. 1256-1257
[42.]
M. Saves, S. Vandentorren, V. Daucourt, C. Marimoutou, M. Dupon, P. Couzigou, et al.
Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998.
AIDS, 13 (1999), pp. F115-F121
[43.]
M. Sulkowski, D. Thomas, R. Chaisson, R. Moore.
Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection.
JAMA, 283 (2000), pp. 74-80
[44.]
M. Den Brinker, F. Wit, P. Wertheim-van Dillen, S. Jurriaans, J. Weel, R. Van Leeuwen, et al.
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
AIDS, 14 (2000), pp. 2895-2902
[45.]
M. Saves, F. Raffi, P. Clevenbergh, B. Marchou, A. Waldner-Combernoux, P. Morlat, et al.
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients.
Antimicrob Agents Chemother, 44 (2000), pp. 3451-3455
[46.]
M. Núñez, R. Lana, J. Mendoza, L. Martín-Carbonero, V. Soriano.
Risk factors for severe hepatic injury following the introduction of HAART.
J Acquir Immun Defic Syndr, 27 (2001), pp. 426-431
[47.]
P. Bonfanti, S. Landonio, E. Ricci, C. Martinelli, P. Fortuna, I. Faggion, et al.
Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy.
J Acquir Immun Defic Syndr, 27 (2001), pp. 316-318
[48.]
A. Monforte A de, R. Bugarini, P. Pezzotti, A. De Luca, A. Antinori, C. Mussini, et al.
Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.
J Acquir Immun Defic Syndr, 28 (2001), pp. 114-123
[49.]
A. Aceti, C. Pasquazzi, B. Zechini, C. De Bac, The LIVERHAART Group.
Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection.
J Acquir Immun Defic Syndr, 29 (2002), pp. 41-48
[50.]
F. Wit, G. Weverling, J. Weel, S. Jurrians, J. Lange.
Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
J Infect Dis, 186 (2002), pp. 23-31
[51.]
M. Núñez, P. Ríos, L. Martín-Carbonero, M. Pérez-Olmeda, J. González-Lahoz, V. Soriano.
Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy.
J Acquir Immun Defic Syndr, 30 (2002), pp. 65-68
[52.]
S. Clark, S. Creighton, B. Portmann, C. Taylor, J. Wendon, M. Cramp.
Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases.
J Hepatol, 36 (2002), pp. 295-301
[53.]
M. Núñez, V. Soriano.
Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients.
J Hepatol, 42 (2005), pp. 290-292
[54.]
R. Selik, R. Byers, M. Dworkin.
Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999.
J Acquir Immun Defic Syndr, 29 (2002), pp. 378-387
[55.]
D.L. Thomas, J. Astemborski, R. Rai, F. Anania, M. Schaeffer, N. Galai, et al.
The natural history of hepatitis C virus infection: host, viral, and environmental factors.
JAMA, 284 (2000), pp. 450-456
[56.]
M. Beld, M. Penning, V. Lukashov, M. McMorrow, M. Roos, N. Pakker, et al.
Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters.
Virology, 244 (1998), pp. 504-512
[57.]
M. Bonacini, S. Govindarajan, L. Blatt, P. Schmid, A. Conrad, K. Lindsay.
Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV-RNA.
J Viral Hepat, 6 (1999), pp. 203-208
[58.]
V. Soriano, J. García-Samaniego, R. Bravo, J. González, A. Castro, J. Castilla, et al.
Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV.
Clin Infect Dis, 23 (1996), pp. 585-591
[59.]
S. Mauss, H. Klinker, A. Ulmer, R. Willers, B. Weissbrich, H. Albrecht, et al.
Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count.
Infection, 26 (1998), pp. 16-19
[60.]
Y. Benhamou, M. Bochet, V. Di Martino, F. Charlotte, F. Azria, A. Coutellier, et al.
Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group.
Hepatology, 30 (1999), pp. 1054-1058
[61.]
M. Puoti, M. Bonacini, A. Spinetti, V. Putzolu, S. Govindarajan, S. Zaltron, et al.
Liver fibrosis progression is related to CD4+ cell depletion in patients with hepatitis C and HIV coinfection.
J Infect Dis, 183 (2001), pp. 134-137
[62.]
C. Martínez-Sierra, A. Arizcorreta, F. Díaz, R. Roldán, L. Martín-Herrera, E. Pérez-Guzmán, et al.
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV.
Clin Infect Dis, 36 (2003), pp. 491-498
[63.]
L. Martín-Carbonero, Y. Benhamou, M. Puoti, J. Berenguer, J. Mallolas, C. Quereda, et al.
Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C – a European collaborative study.
Clin Infect Dis, 38 (2004), pp. 128-133
[64.]
M.E. Eyster, L.S. Diamondstone, J.M. Lien, W.C. Ehmann, S. Quan, J.J. Goedert, et al.
Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with HIV. A multicenter hemophilia cohort study.
J Acquir Immun Defic Syndr, 6 (1993), pp. 602-610
[65.]
A. Sánchez-Quijano, J. Andreu, F. Gavilán, F. Luque, M.A. Abad, B. Soto, et al.
Influence of HIV type 1 infection on the natural history of chronic parenteral acquired hepatitis C.
Eur J Clin Microbiol Infect Dis, 14 (1995), pp. 949-953
[66.]
J. Rockstroh, U. Spengler, T. Sudhop, S. Ewig, A. Theisen, U. Hammerstein, et al.
Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV.
Am J Gastroenterol, 91 (1996), pp. 2563-2568
[67.]
B. Soto, A. Sánchez-Quijano, L. Rodrigo, J.A. Del Olmo, M. García-Bengoechea, J. Hernández-Quero, et al.
HIV infection modifies the natural history of chronic parenteral acquired hepatitis C with an unusually rapid progression to cirrhosis.
J Hepatol, 26 (1997), pp. 1-5
[68.]
J. García-Samaniego, M. Rodríguez, J. Berenguer, R. Rodríguez-Rosado, J. Carbó, V. Asensi, et al.
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.
Am J Gastroenterol, 96 (2001), pp. 179-183
[69.]
M. Puoti, R. Bruno, V. Soriano, F. Donato, G. Gaeta, G. Quinzan, et al.
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.
AIDS, 18 (2004), pp. 2285-2293
[70.]
S. Darby, D. Ewart, P. Giangrande, R. Spooner, C. Rizza, G. Dusheiko, et al.
Mortality from liver cancer and liver disease in hemophiliac men and boys in the UK given blood product contaminated with hepatitis C.
Lancet, 350 (1997), pp. 1425-1431
[71.]
M. Puoti, A. Spinetti, A. Ghezzi, F. Donato, S. Zaltron, V. Putzolu, et al.
Mortality for liver disease in patients with HIV-infection: a cohort study.
J Acquir Immun Defic Syndr, 24 (2000), pp. 211-217
[72.]
J. Macías, I. Melguizo, F. Fernández-Rivera, A. García-García, J.A. Mira, A. Ramos, et al.
Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-1-infected patients receiving potent antiretroviral therapy.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 775-781
[73.]
F. Bonnet, P. Morlat, G. Chene, P. Mercie, D. Neau, I. Chossat, et al.
Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.
HIV Med, 3 (2002), pp. 195-199
[74.]
N. Qurishi, C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer, T. Sauerbruch, et al.
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection.
Lancet, 362 (2003), pp. 1708-1713
[75.]
M. Bonacini, N. Bzowej, S. Louie, A. Wohl.
Survival in patients with HIV infection and viral hepatitis B or C.
AIDS, 18 (2004), pp. 2039-2045
[76.]
Y. Benhamou, V. Di Martino, M. Bochet, G. Colombet, V. Thibault, A. Liou, et al.
Factors affecting liver fibrosis in HIV and hepatitis C virus coinfected patients: impact of protease inhibitor therapy.
Hepatology, 34 (2001), pp. 283-287
[77.]
J. Macias, V. Castellano, N. Merchante, R. Palacios, J.A. Mira, C. Saez, et al.
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
AIDS, 18 (2004), pp. 767-774
[78.]
D. Fuster, R. Planas, R. Muga, A. Ballesteros, J. Santos, J. Tor, et al.
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
AIDS Res Hum Retroviruses, 20 (2004), pp. 1293-1297
[79.]
M. Pérez-Olmeda, M. Núñez, M. Romero, J. González, A. Castro, J. Arribas, et al.
Pegylated interferon-a2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
AIDS, 17 (2003), pp. 1023-1028
[80.]
A. Ballesteros, S. Franco, D. Fuster, R. Planas, M. Martínez, L. Acosta, et al.
Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches.
AIDS, 18 (2004), pp. 59-66
[81.]
L. Moreno, C. Quereda, A. Moreno, M. Pérez-Elías, A. Antela, J. Casado, et al.
Pegylated interferon-a2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
AIDS, 18 (2004), pp. 67-73
[82.]
R. Chung, J. Andersen, P. Volberding, G. Robbins, T. Liu, K. Sherman, et al.
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
N Engl J Med, 351 (2004), pp. 451-459
[83.]
F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, et al.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients.
JAMA, 292 (2004), pp. 2839-2848
[84.]
F. Torriani, M. Rodríguez-Torres, J. Rockstroh, E. Lissen, J. González-García, A. Lazzarin, et al.
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
N Engl J Med, 351 (2004), pp. 438-450
[85.]
M. Laguno, J. Murillas, J.L. Blanco, E. Martínez, R. Miquel, J.M. Sánchez-Tapias, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
AIDS, 18 (2004), pp. F27-F36
[86.]
V. Soriano, M. Pérez-Olmeda, P. Ríos, M. Núñez, J. García-Samaniego, J. González-Lahoz.
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
AIDS Res Hum Retroviruses, 20 (2004), pp. 351-354
[87.]
K. Sherman, N. Shire, S. Rouster, M. Peters, M. James Koziel, R. Chung, et al.
Viral kinetics in hepatitis C or hepatitis C/HIV-infected patients.
Gastroenterology, 128 (2005), pp. 313-327
[88.]
J. Vrolijk, J. Kwekkeboom, H. Janssen, B. Hansen, P. Zondervan, A. Osterhaus, et al.
Pre-treatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.
J Infect Dis, 188 (2003), pp. 1528-1532
[89.]
M. Manns, J. McHutchison, S. Gordon, V. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.
Lancet, 358 (2001), pp. 958-965
[90.]
M. Fried, M. Shiffman, K. Reddy, C. Smith, G. Marinos, F. Goncales, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med, 347 (2002), pp. 975-982
[91.]
J. Wong, W. Bennett, R. Koff, S. Pauker.
Pre-treatment evaluation of chronic hepatitis C. Risks, benefits, and costs.
JAMA, 280 (1998), pp. 2088-2093
[92.]
V. Soriano, L. Martín-Carbonero, J. García-Samaniego.
Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?.
AIDS, 17 (2003), pp. 751-753
[93.]
G. Spinzi, G. Minoli.
To biopsy or not to biopsy.
Hepatology, 34 (2001), pp. 438-439
[94.]
A. Andriulli, A. Mangia, G. Niro, E. Caturelli.
To biopsy or not to biopsy.
Hepatology, 34 (2001), pp. 438
[95.]
J. Dienstag.
The role of liver biopsy in chronic hepatitis C.
Hepatology, 36 (2002), pp. 152-160
[96.]
P. Bedossa, D. Dalgere, V. Paradis.
Sampling variability of liver fibrosis in chronic hepatitis C.
Hepatology, 38 (2003), pp. 1449-1457
[97.]
D. Strader, T. Wright, D. Thomas, L. Seeff.
Diagnosis, management, and treatment of hepatitis C.
Hepatology, 39 (2004), pp. 1147-1171
[98.]
Sulkowski M, Mehta S, Torbenson M, Moore R, Thomas D. Unexpected significant liver disease among HIV/HCV-coinfected persons with minimal fibrosis on initial liver biopsy. 12th CROI, Boston, February 2005 [abstract 121].
[99.]
F. Kuehne, U. Bethe, K. Freedberg, S. Goldie.
Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness.
Arch Intern Med, 162 (2002), pp. 2545-2556
[100.]
M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, F. Kazemi, et al.
Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.
Hepatology, 41 (2005), pp. 48-54
[101.]
L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, M. Haaser, et al.
Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
Gastroenterology, 128 (2005), pp. 343-350
[102.]
R. Myers, Y. Benhamou, F. Imbert-Bismut, V. Thibault, M. Bochet, F. Charlotte, et al.
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
AIDS, 17 (2003), pp. 721-725
[103.]
Sterling R, Lissen E, Clumeck N. Can routine non-invasive tests predict liver histology in HIV/HCV co-infection? Analysis of patients entering the APRICOT. 12th CROI, Boston, February 2005 [abstract 120].
[104.]
B. Gao, F. Hong, S. Radaeva.
Host factors and failure of interferon treatment in hepatitis C virus.
Hepatology, 39 (2004), pp. 880-890
[105.]
S. Zeuzem.
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?.
Ann Intern Med, 140 (2004), pp. 370-381
[106.]
S. Vento, G. Di Perri, M. Cruciani, T. Garofano, E. Concia, D. Bassetti.
Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection.
Lancet, 341 (1993), pp. 958-959
[107.]
A. Pesce, B. Taillan, E. Rosenthal.
Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients.
Lancet, 341 (1993), pp. 1597
[108.]
V. Soriano, I. Maida, J. García-Samaniego, M. Núñez, P. Barreiro, J. González-Lahoz.
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
Antivir Ther, 9 (2004), pp. 987-992
[109.]
D. Sylvestre.
Treating hepatitis C in methadone maintenance patients: an interim analysis.
Drug Alcohol Depend, 67 (2002), pp. 117-123
[110.]
M. Backmund, K. Meyer, V. Von Zielonka, D. Eichenlaub.
Treatment of hepatitis C infection in injection drug users.
Hepatology, 34 (2001), pp. 188-193
[111.]
B. Edlin.
Prevention and treatment of hepatitis C in injecting drug users.
Hepatology, 36 (2002), pp. 210-219
[112.]
NIH Consensus Development Conference Statement: management of hepatitis C.
Gastroenterology, 123 (2002), pp. 2082-2099
[113.]
G. Davis, J. Albrecht, S. Cook, D. Rosenberg.
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
Hepatology, 38 (2003), pp. 645-652
[114.]
F. Torriani, R. Ribeiro, T. Gilbert, U. Schrenk, M. Clauson, D. Pacheco, et al.
HCV and HIV dynamics during HCV treatment in HIV/HCV coinfection.
J Infect Dis, 188 (2003), pp. 1498-1507
[115.]
V. Soriano, M. Núñez, N. Camino, P. Barreiro, J. García-Samaniego, J. González-Lahoz.
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Antivir Ther, 9 (2004), pp. 505-509
[116.]
M. Núñez, N. Camino, B. Ramos, M.A. Berdún, P. Barreiro, E. Losada, et al.
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
Antivir Ther, 10 (2005), pp. 657-662
[117.]
M. Buti, A. Valdés, F. Sánchez-Ávila, R. Estebán, Y. Lurie.
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
Hepatology, 37 (2003), pp. 1226-1227
[118.]
A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley, T. Layden, et al.
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy.
Science, 282 (1998), pp. 103-107
[119.]
J. Pawlotsky.
Use and interpretation of virological tests for hepatitis C.
Hepatology, 36 (2002), pp. 65-73
[120.]
J. Brouwer, F. Nevens, F. Bekkering, N. Bourgeois, H. Van Vlierberghe, C. Weegink, et al.
Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomized trial in 300 patients.
J Hepatol, 40 (2004), pp. 689-695
[121.]
Núñez M, Maida I, Berdún M, Soriano V. Efficacy and safety of pegylated interferon alpha-2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. 44th ICAAC; Washington, DC; October 2004 [abstract V-1148].
[122.]
K. Lindahl, L. Stahle, A. Bruchfeld, R. Schvarcz.
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
Hepatology, 41 (2005), pp. 275-279
[123.]
N. Dixit, J. Layden-Almer, T. Layden, A. Perelson.
Modeling how ribavirin improves interferon response rates in hepatitis C virus infection.
Nature, 432 (2004), pp. 922-924
[124.]
D. Dieterich.
Treatment of hepatitis C and anemia in HIV-infected patients.
J Infect Dis, 185 (2002), pp. 128-137
[125.]
L. Alri, M. Duffaut, J. Selves.
Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomised trial.
J Hepatol, 35 (2001), pp. 272-278
[126.]
C. Camma, M. Giunta, P. Andreone, A. Craxi.
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
J Hepatol, 34 (2001), pp. 593-602
[127.]
H. Yoshida, Y. Arakawa, M. Sata, S. Nishiguchi, M. Yano, S. Fujiyama, et al.
Interferon therapy prolongs life expectancy among chronic hepatitis C patients.
Gastroenterology, 123 (2002), pp. 483-491
[128.]
V. Soriano, R. Bravo, J. García-Samaniego, J. González, P.M. Odriozola, E. Arroyo, et al.
CD4+ T lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C.
AIDS, 8 (1994), pp. 1621-1622
[129.]
A. Lafeuillade, G. Hittinger, S. Chapadaud.
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lancet, 357 (2001), pp. 280-281
[130.]
G. Moyle.
Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies.
AIDS Rev, 3 (2001), pp. 150-156
[131.]
C. De Mendoza, M. Sánchez-Conde, E. Timmermans, M. Buitelaar, M.P. De Baar, J. González-Lahoz, et al.
Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin.
Antivir Ther, 10 (2005), pp. 557-561
[132.]
S. Mauss, W. Valenti, J. DePamphilis, F. Duff, L. Cupelli, S. Passe, et al.
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrosis during interferon therapy.
AIDS, 18 (2004), pp. F21-F25
[133.]
A. Rendon, M. Núñez, M. Romero, P. Barreiro, L. Martín-Carbonero, J. García-Samaniego, et al.
Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients.
J Acquir Immune Defic Syndr, 39 (2005), pp. 401-405
[134.]
M. Fried.
Side effects of therapy of hepatitis C and their management.
Hepatology, 36 (2002), pp. 237-244
[135.]
S. Hadziyannis, H. Sette, T. Morgan, V. Balan, M. Diago, P. Marcellin, et al.
Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C.
Ann Intern Med, 140 (2004), pp. 346-355
[136.]
N. Afdhal, D. Dieterich, P. Pockros, E. Schiff, M. Shiffman, M. Sulkowski, et al.
Epoetin alfa maintains ribavirin dose in HCV-infected patients. A prospective, double-blind randomized controlled study.
Gastroenterology, 126 (2004), pp. 1302-1311
[137.]
R. Gish, S. Arora, D. Nelson, H. Fernández, K. Lamon.
Safety and efficacy of Viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naïve patients.
J Hepatol, 40 (2004), pp. 141-142
[138.]
M. Laguno, J. Blanch, J. Murillas, J.L. Blanco, A. León, M. Lonca, et al.
Depressive symptoms after initiation of interferon therapy in HIV-infected patients with chronic hepatitis C.
Antivir Ther, 9 (2004), pp. 905-909
[139.]
B. Zingman, H. Morales, F. Rodríguez.
HCV evaluation and treatment can be improved by a multidisciplinary HIV/HCV co-infection program: results from the first year of a program co-located at an urban HIV primary care clinic.
Gastroenterology, 128 (2005), pp. A726
[140.]
Breilh D. Plasma target concentration of ribavirin in HCV/HIV-co-infected patients. 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston, MA [abstract 928].
[141.]
G. Drusano, S. Preston.
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
J Infect Dis, 189 (2004), pp. 964-970
[142.]
R. Planas, D. Fuster, J. González.
Multicenter pilot study to assess the efficacy and safety of prolonging treatment with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in HIV and HCV coinfected patients without early virological response.
Gastroenterology, 128 (2005), pp. A682
[143.]
Núñez M, Maida I, Berdún A. Efficacy and safety of pegInterferon-a-2a plus ribavirin (pegIFN + RBV) for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. The virological response obtained at the end of treatment is among the highest reported so far in this population. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract V-1148].
[144.]
M. Glesby, R. Bassett, B. Alston-Smith, C. Fichtenbaum, E. Jacobson, C. Brass, et al.
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Clin Infect Dis, 191 (2005), pp. 686-693
[145.]
R. Myers, Y. Benhamou, M. Bochet, V. Thibault, D. Mehri, T. Pynard.
Pegylated interferon alpha-2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapdsers to IfN-based therapy.
AIDS, 18 (2004), pp. 75-79
[146.]
R. Chung, J. Andersen, P. Volberding, G. Robbins, T. Liu, K. Sherman, et al.
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
N Engl J Med, 351 (2004), pp. 451-459
Copyright © 2006. Elsevier España S.L.. Todos los derechos reservados
